Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phospholamban gene mutations are not associated with hypertrophic cardiomyopathy in patients from southern Poland.

Kardiologia polska - 1 Jan 2011

Petkow-Dimitrow Paweł, Kieć-Wilk Beata, Kwaśniak Małgorzata, Mikołajczyk Magdalena, Dembińska-Kieć Aldona

Abstract excerpt

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a genetic disease. The role of phospholamban (PLN) gene mutations is the development of HCM has not been established. AIM: To screen for PLN gene mutations in a group of HCM patients from the southern Poland. METHODS: We included 50 consecutive patients (31 males, mean age 42 ± 14 years) diagnosed with HCM on the basis of typical clinical, echocardiographic, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcium-Binding Proteins
Share to Cardiomyopathy, Hypertrophic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to PLN gene

Share to Genetic Predisposition to Disease

Share to Mutation

Share to Poland

Source

Identifiers

PMID: 21332051

Genes

PLN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phospholamban gene mutations are not associated with hypertrophic cardiomyopathy in patients from southern Poland.PMID 21332051Read ↗

Phospholamban gene mutations are not associated with hypertrophic cardiomyopathy in a Northern Greek population.Semantic proximity Read ↗

A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations.Semantic proximity Read ↗

PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing.Semantic proximity Read ↗

Prevalence and cardiac phenotype of patients with a phospholamban mutationSemantic proximity Read ↗

Genetic landscape of phospholamban cardiomyopathiesSemantic proximity Read ↗

Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy.Semantic proximity Read ↗

No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure.Semantic proximity Read ↗

Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and humanSemantic proximity Read ↗

Mutations in the human phospholamban gene in patients with heart failureSemantic proximity Read ↗

Molecular Characterization of Phospholamban and Reninangiotensin System Genes Mutations and Clinical Epidemiology in Human CardiomyopathySemantic proximity Read ↗

Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C>G mutation.Semantic proximity Read ↗

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.